1. Scrip
  2. >>Business

Start-Up Quarterly Statistics, Q4 2016

 
• By Deanna Kamienski

A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.

trading

Biopharma start-ups brought in nearly two-and-a-half times as much funding in the fourth quarter as in the third quarter. Novartis AG was one of five big pharma companies to pen an alliance with a new and emerging therapeutics firm; the company also signed an acquisition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.